Syneron Named to MDB Capital Group's "Best & Brightest" List
03 Marzo 2011 - 8:00AM
Marketwired
Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic
device company, announced today that it has been included in MDB
Capital Group's "Best & Brightest" list of 150 innovative
leaders for 2011.
MDB's Best & Brightest list is drawn from the universe of
public companies with at least one U.S. patent and a market
capitalization under $500 million. Companies included in the Best
& Brightest list are ranked in the 90th percentile for
technology leadership from more than 1,500 companies with U.S.
patents granted.
Lou Scafuri, Chief Executive Officer of Syneron, commented,
"Syneron's inclusion on MDB's Best & Brightest list is a
testament to the strength of our innovative portfolio and pipeline
of aesthetic devices and products for the professional and home-use
markets. It also demonstrates our commitment to superior science
and excellent clinical results, both of which create trust in our
products. Looking forward, we will continue to have a strong focus
on developing and acquiring best-in-class, category-creating
technologies for aesthetic applications."
Syneron is celebrating 10 years of successful aesthetic
treatments with its proprietary elos technology. elos is the first
and only technology that simultaneously harnesses the power of both
bi-polar radio frequency (RF) and optical energy (either laser or
light). The Company also employs other proprietary technologies and
patented systems for aesthetic procedures in the professional and
home-use markets. Syneron recently unveiled new cutting-edge
aesthetic products at the 69th Annual Meeting of the American
Academy of Dermatology (AAD). The newly-launched products include
ePrime™ Energy-Based Dermal Volumizer™, CO2RE versatile Fractional
CO2 Resurfacing System and elure™ Advanced Skin Lightening
Technology™. In addition, the Company featured the revolutionary
eMatrix® complete Sublative Rejuvenation® system at the AAD.
About MDB Capital Group LLC
MDB Capital is an institutional research and investment banking
firm that focuses exclusively on companies that possess market
changing, disruptive intellectual property. For more information,
visit www.mdb.com.
About Syneron Medical Ltd.
Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global
aesthetic device company with a comprehensive product portfolio and
a global distribution footprint. The Company's technology enables
physicians to provide advanced solutions for a broad range of
medical-aesthetic applications including body contouring, hair
removal, wrinkle reduction, rejuvenation of the skin's appearance
through the treatment of superficial benign vascular and pigmented
lesions, and the treatment of acne, leg veins and cellulite. The
Company sells its products under two distinct brands, Syneron and
Candela. Founded in 2000, the corporate, R&D, and manufacturing
headquarters for Syneron Medical Ltd. are located in Israel.
Syneron also has R&D and manufacturing operations in the US.
The company markets and services and supports its products in 86
countries. It has offices in North America, France, Germany, Italy,
Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and
distributors worldwide. Additional information can be found at
www.syneron.com.
Contacts: Asaf Alperovitz Chief Financial Officer + 972
73 244 2283 Email: Email Contact Nick Laudico/Zack Kubow The Ruth
Group 646-536-7030/7020 Email: Email Contact / Email Contact
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024